Nextstellis FDA Approval History
Last updated by Judith Stewart, BPharm on May 2, 2021.
Nextstellis (drospirenone and estetrol) is a progestin and estrogen combination indicated for use by females of reproductive potential to prevent pregnancy.
- Nextstellis is the first oral contraceptive to contain estetrol (E4), a synthetic analogue of a native estrogen present during pregnancy.
- Nextstellis tablets are taken once daily, with 24 active tablets and 4 inert tablets in each 28 day cycle.
- Nextstellis comes with a boxed warning for cigarette smoking and serious cardiovascular events. Common adverse reactions include bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, increased weight, and decreased libido.
Development timeline for Nextstellis
|Apr 15, 2021||Approval FDA Approves Nextstellis (drospirenone and estetrol) Oral Contraceptive for Birth Control|
|Apr 16, 2020||Mayne Pharma Submits NDA for E4/DRSP to the FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.